FOL100

Phase 1Small molecule

FFollicle Pharma Ltd

FOL100 is one of 28 small molecule programs targeting Androgenetic Alopecia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Androgenetic AlopeciaActive, not recruiting

Androgenetic AlopeciaPhase 1

Active, not recruiting

Competition

Competitive Landscape

62 competitors in Androgenetic Alopecia

#DrugCompanyPhaseTrials

Rogaine

Pfizer

Approved

11 2

Aldactone

Pfizer

Approved

1 3

Depakote

Avodart

4 5

XEOMIN

MMerz Pharmaceuticals GmbH

Phase 2

—6

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Zolymbus

1 8

Platelet Rich Plasma

ZZagazig University

Phase 2

2 9

Lactobacillus Reuteri

TTulane University School of Medicine

Phase 2

1 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Androgenetic Alopecia1 trial

Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia

Recruiting·FFollicle Pharma Ltd·Phase 1·NCT05611593·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FOL100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOL100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOL100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Follicle Pharma Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: FFollicle Pharma Ltd

FOL100

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Androgenetic Alopecia1 trial

References

Drug Info

Quick Facts

Related News